Preclinical Research

 
News Articles for Preclinical Research top ^
2014/9/17
At the 2014 World Molecular Imaging Congress (WMIC, www.wmis.org ), Bruker today introduces new products for improved performance and customer experience in preclinical imaging, and announces related achievements: NEW PRODUCT: SkyScan™ 1278 , the world’s fastest, low-dose, high-resolution micro-CT: With the launch of the next-generation SkyScan 1278 micro-CT system for in vivo X-ray computed tomography, Bruker is addressing the latest needs of preclinical imaging scientists striving to reduce the radiation dose used in animal studies, while maintaining highest image quality.
Sign-up for Bruker Introduces New Products for Preclinical Imaging at WMIC 2014 investment picks
GAITHERSBURG, Md., Sept.
Sign-up for CORRECTING and REPLACING -- Novavax to Present RSV Vaccine Preclinical Results at ICAAC investment picks
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company’s therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), a rare inherited liver disorder that often results in progressive and severe kidney damage.
Sign-up for Researchers Demonstrate Promise of Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria Type 1 (PH1) investment picks
SAGE Therapeutics (NASDAQ: SAGE) today presented preclinical data on its second-generation neuroactive steroid, SAGE-217, at the Twelfth Eilat Conference on New Anti-Epileptic Drugs in Madrid, Spain.
Sign-up for SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs investment picks
NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis, or fatty liver disease) demonstrated that oral administration of the Company's lead galectin-3 inhibitor, GR-MD-02, resulted in significant disease improvement.
Sign-up for Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced the publication of promising preclinical data demonstrating the application of the Company’s novel Gene Silencing Oligonucleotides (GSOs) to inhibit microRNAs implicated in neovascularization, a process that involves the proliferation of blood vessels in tissue and is crucial for recovery following cardiovascular events.
Sign-up for Idera Pharmaceuticals and Collaborators Publish Promising Preclinical Data Targeting microRNA with Gene Silencing Oligonucleotide Technology investment picks
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2 nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada.
Sign-up for AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference investment picks
Together with Excellence Cluster Cardio-Pulmonary System (ECCPS) and TransMIT Gesellschaft für Technologietransfer mbH (TransMIT), Sangui is investigating new therapeutic approaches to treating septic shock and acute respiratory distress syndrome (ARDS). Owing to their incidence rate, complexity and poor prognosis, the two diseases constitute a huge challenge in both in terms of their socio-economic impact and the associated intensive medical care, and incur unacceptably high mortality rates, despite progress made in intensive medicine.
Sign-up for Sangui BioTech: Start of preclinical trials investment picks
GAITHERSBURG, Md., Sept.
Sign-up for Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC investment picks
Interim Data on First 11 Patients in the Ongoing Phase 2/3 HOPEMD Study Suggest Cabaletta to be Safe and Well Tolerated with No Drug Related Adverse Events TEL AVIV, Israel, Sept.
Sign-up for BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Preclinical Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Precision Manufacturing  |  Next: Preclinical Results